Peptides MEX / Articles
Ipamorelin and CJC-1295: assessing combination claims
Two compounds may appear in the same hormonal explanation without evidence establishing the effectiveness of combining them. Reviewing such a claim requires identifying each substance and checking whether the source actually tested the combination.
Updated · Sources and editorial standards
A mechanism hypothesis is not a combination trial
The original ipamorelin paper characterizes a growth-hormone secretagogue. That characterization supports pharmacological questions, but it does not establish the behavior of a mixture with CJC-1295. A conclusion must retain the intervention the experiment actually evaluated.
Sources: [1]
DAC and no-DAC identities must stay separate
The FDA review distinguishes CJC-1295-related substances and specifies the chemical unit added to the DAC form. An abbreviated name can conceal that difference. Before using a publication as support, check whether its studied identity matches the one described in the claim.
Sources: [3]
What the human CJC-1295 paper contributes
Teichman and colleagues studied a long-acting GHRH analog and measured pharmacokinetic and hormonal variables in healthy adults. This was not a trial of ipamorelin mixed with a no-DAC reference. Its findings should not automatically be assigned to that different formulation.
What evidence a synergy claim needs
As a reading criterion, look for a study identifying both substances, using appropriate comparisons and defining the additional effect it aims to demonstrate. Sharing a general pathway or adding findings from separate papers does not prove synergy. Nor should an isolated hormonal signal be converted into a functional or clinical outcome.
Questions about this reference
Does the human CJC-1295 study establish the ipamorelin combination?
No. The cited design studied long-acting CJC-1295 rather than that combination.
Can DAC CJC-1295 results be assigned to a no-DAC reference?
Not without establishing that the comparison is valid. The modification is part of the identity and can change pharmacological interpretation.
Sources and original reading
- Raun et al.: discovery and pharmacology of ipamorelin (1998)
- Teichman et al.: long-acting CJC-1295 in healthy adults (2006)
- FDA: CJC-1295-related substances, advisory briefing (2024)
Content updated: . How this content is prepared and checked.